PLENARY – The Future of Diabetes Therapies: GLP-1s and Beyond

Speaker: Marc Y. Donath

Location: Constitution Hall

10:30 – 11:45

PREMATURE OVARIAN INSUFFICIENCY

Speaker: Dr. Michelle Jacobson, Dr. Illiana Lega

Moderator: Dr. Donna Vine

Room: 206

At the end of this session, participants should be able to:

• Summarize the etiologies, clinical features, and diagnostic criteria for premature ovarian insufficiency, including genetic, autoimmune, and iatrogenic causes.
• Critically assess the quality, strengths, and limitations of clinical trials and observational studies evaluating the efficacy and safety of hormone replacement strategies in women with POI.
• Apply an evidence-based approach to selecting and individualizing hormone replacement therapy for patients with POI, considering factors such as age of diagnosis, comorbidities, route of administration, and long-term health outcomes.

ACCREDITED SYMPOSIA – EVOLUTION OF GLP-1 AND GIP/GLP1 THERAPIES: FROM TRIAL EVIDENCE TO CLINICAL PRACTICE

Speaker: Dr. Kim Connelly, Dr. Alice Cheng, Lori Berard

Moderator: Dr. Kevin Saunders

Room:

At the end of this session, participants should be able to:

• Apply cardiovascular outcomes trial evidence to guide GLP-1 RA and GIP/GLP-1 RA therapy selection in T2D
• Select and titrate GIP/GLP-1 RA and GLP-1 RA therapies based on patient-specific factors
• Integrate GIP/GLP-1 and GLP-1-based therapies into management plans for patients with metabolic and cardiovascular comorbidities
• Optimize adherence and outcomes through adverse effect management strategies

ACCREDITED SYMPOSIA – THE CARDIO-RENAL-METABOLIC APPROACH – GLP-1 AND GIP/GLP RAS IN DIABETES

Speaker: Dr. Akshay Jain, Dr. Grace Chua, Dr. Philip McFarlane, Michael Bovin

Moderator: Dr. Jeff Habert

Room:

At the end of this session, participants should be able to:

• Evaluate the clinical evidence supporting the use of GLP-1 and GIP/GLP receptor agonists (RAs), including semaglutide and tirzepatide, in the management of diabetes and related cardiometabolic conditions
• Apply principles of holistic, multi-organ management to optimize care for patients with metabolic disease, recognizing the impact of comorbidities and the systemic benefits of GLP-1 and GIP/GLP RA therapies/li>
• Implement evidence-based strategies to initiate and optimize GLP-1 and GIP/GLP RA therapy in clinical practice within collaborative care models to improve patient outcomes

RARE DISEASE ROUNDS – SHARP NEEDLES IN THE CROWD: FRESH APPORACHES TO COMMON CHALLENGES IN PITUITARY ENDOCRINOPATHIES

Speaker: Dr. Shereen Ezzat, Dr. Luciana Martel-Duguech, Dr. Jessica MacKenzie-Feder

Moderator: Dr. Matthieu St Jean

Room: 205

At the end of this session, participants should be able to:

• Objectives in development

RESIDENTS ABSTRACT CLINICAL VIGNETTES, RESEARCH PROJECTS ORAL PRESENTATIONS

Speakers: Dr. Taylor Sidhu, Dr. Laura Senior, Dr. Florence Perreault, Dr. Agathe Rio, Dr. Gabriela Szuman, Dr. Sandrine Leblanc-Savignac, Dr. Armin Farahvash

Moderator: Dr. Tayyab Khan

Room: 205

16:00 – 17:00

HAROLD COPP BASIC SCIENCE LECTURE: OSTEOGENESIS IMPERFECTA: MECHANISMS, MODELS, AND THERAPEUTIC IMPLICATIONS

Speaker: Dr. Frank Rauch

Moderator: Dr. Sara Awad

Room: 205

At the end of this session, participants should be able to:

• Discuss the latest research on genetic and molecular mechanisms osteogenesis imperfecta (OI) and the implications on bone matrix development and skeletal fragility using animal models.
• Evaluate the genetic testing, imaging modalities and biomarkers of bone turnover for diagnosis and monitoring of OI and related phenotypes of metabolic bone disease.
• Assess current and emerging advances in technologies and therapeutic approaches for treatment of OI.

WORKSHOP:  CURRENT AND NOVEL APPROACHES TO THYROID NODULES: WHAT TO TELL YOUR PATIENTS
Speaker: Dr. Jesse Pasternak

Moderators: Dr. Sana Ghaznavi

Room: 203 B/D

At the end of this workshop, participants should be able to:

• Describe the indications for Radiofrequency Ablation (RFA) and appropriate patient selection for this procedure.
• Compareand contrast treatment options for benign, hyperfunctional, and malignant thyroid nodules—including RFA, surgery, and active surveillance.
  • Describetechnical aspects of RFA including complications and post-RFAultrasound findings.
  • Evaluate current evidence and identify areas of uncertainty or controversy surrounding RFA procedures in thyroid nodule management.

Speaker: Dr. Michael Cusimano; Dr. Kirstie Lithgow

Moderator:

Room: 205

At the end of this session, participants should be able to:

• Describe the epidemiology and presentation of craniopharyngioma.
• Review the pathology and genetics of craniopharyngioma.
• Contrast papillary versus adamantinomatous subtypes.
• Review the role of surgery, radiation and BRAF targeted treatment modalities.

Speaker: Dr. Ralf Paschke, Dr. Sam Wiseman, Dr. Marie-Hélène Massicotte, Dr. Sana Ghaznavi

Moderator: Dr. Vicki Munro

Room: 201 A-F

At the end of this session, participants should be able to:

• Summarize the current international consensus guidelines on the diagnosis, risk stratification, and initial management of low-risk differentiated thyroid cancer, including criteria for active surveillance versus surgical intervention.
• Critically evaluate the evidence supporting de-escalation strategies in low-risk thyroid cancer management, including reduced extent of surgery, selective use of radioactive iodine, and individualized TSH suppression targets.
• Apply a patient-centered, evidence-based approach to counseling and managing individuals with low-risk thyroid cancer, incorporating shared decision-making principles and long-term surveillance strategies.

Speaker: Nazlie Parast, Dr. Irena Druce, Dr. Peter Liu, Dr. Jasmine Bahrami

Moderator: Dr. James Kim

Room:

At the end of this session, participants should be able to:

• Analyze sex-specific risk factors and clinical presentations in cardiometabolic disease to improve diagnosis and early intervention strategies (CanMEDS roles: Medical Expert, Scholar)
• Apply sex-informed treatment approaches across care perspectives (endocrinology, cardiology, primary care, pharmacy, nursing) to optimize patient outcomes (CanMEDS roles: Collaborator, Leader)
• Evaluate sex-based disparities in cardiometabolic care delivery and implement strategies to ensure equitable, guideline-directed therapy for all patients (CanMEDS roles: Professional, Health Advocate)

Speaker: Dr. Sheldon Tobe, Dr. Rick Ward, Dr. Jo-anne Wilson

Moderator: Dr. Calvin Ke

Room:

At the end of this session, participants should be able to:

• Integrate systematic screening protocols for chronic kidney disease for individuals with diabetes according to current Canadian guidelines
• Apply evidence-based pharmacotherapy strategies to prevent or delay CKD progression in individuals with diabetes
• Implement patient-centred communication techniques to engage asymptomatic individuals with diabetes in early CKD prevention and treatment
• Determine appropriate timing and criteria for nephrology referral while managing common complications such as hyperkalemia in primary care settings

Speaker: Dr. Isabelle Hardy, Dr. Afshan Zahedi

Moderator: Dr. Alice Cheng

Room: 205

At the end of this session, participants should be able to:

• Define and stage thyroid eye disease
• Initiate endocrinologist-appropriate treatments
• Determine when to refer to ophthalmology
• Recognize the lived experience of thyroid eye disease

Speakers:

Moderator: Dr. Robert Goldberg

Room: 201 A-F

Speaker: Dr. Sam Wiseman

Moderator: Dr. Breay Paty

Room: 205

At the end of this session, participants should be able to:

• Objectives in development

Speaker: Dr. Marie Eva Pigeyre

Moderator: Dr. Yuan Kong

Room: 205

At the end of this session, participants should be able to:

• To define and discuss the specific lipid disorders and clinical scenarios where genetic testing is clinically indicated, including familial hypercholesterolemia (FH) and other rare monogenic dyslipidemias.
• To evaluate and interpret the clinical relevance of genetic mutations associated with dyslipidemia, with a focus on autosomal recessive (AR) and autosomal dominant (AD) inheritance patterns, the implications of variants of undetermined significance (VUS), and the role of variable penetrance in the expression of lipid disorders.
• To outline the necessary follow-up steps and additional clinical workup after the identification of genetic changes associated with lipid disorders, including guidelines on  familial screening for different genetic variations to identify at-risk family members and manage early detection.

Room: 104 D

Speaker: Muhammad Mamdani, PharmD, MA, MPH

Location: Constitution Hall

Speaker: Dr. Peter Senior, Dr. Peter Lin, Susie Jin RPh, CDE, CRE

Moderator: Dr. Elizabeth Rosolowsky

Room:

At the end of this session, participants should be able to:

• Review the epidemiology, staging, and clinical landscape of autoimmune T1D
• Devise strategies and early detection protocols to assess the risk of developing autoimmune T1D and prevent complications such as DKA
• Explore treatment options to delay the onset and progression of autoimmune T1D

Speaker: Dr. Giada Sebastiani, Dr. Shahebina Walji, Dr. Chantal Bémeur

Moderator: Dr. Harpreet Bajaj

Room:

At the end of this session, participants should be able to:

• Objectives in development

Speaker: Dr. Amanda Berberich, Dr. Aliya Khan, Dr. Leanne Ward

Moderator: Dr. Yuan Kong

Room: 205

At the end of this session, participants should be able to:

• Recognize the clinical presentation and diagnostic criteria for homozygous familial hypercholesterolemia
• Evaluate and apply current standard and emerging management strategies for patients with HoFH to optimize patient outcomes and quality of life
• Describe current approaches to the diagnosis and management of hypoparathyroidism
• Evaluate indications for parathyroid hormone (PTH) replacement therapy and apply appropriate protocols in clinical practice.
• Analyze innovative diagnostic techniques for identifying PHEX gene variants in individuals with de novo x-linked hypophosphatemia (XLH).
• Design optimized medication strategies to improve health outcomes in pediatric patients with XLH.

Speaker: Dr. Richard Auchus

Moderator: Dr. Matthieu St Jean

Room: 206

At the end of this session, participants should be able to:

• Review the gene variants and metabolic consequences of classical and non-classical CAH.
• Discuss current treatments and monitoring of CAH based on the most recent guidelines.
• Describe new and future therapeutic approaches for treatment of CAH.

Dr. Donald Morrish – Dr. Robert Voplé Distinguished Service Award

Dr. Elizabeth Rosolowsky – Dr. Harvey Guyda Educator of the Year Award

Dr. Mohmmad Jay – Dr. Fernand Labrie Fellowship Research Grant

Dr. Philip Britz-McKibbon – Thyroid Foundation of Canada Research Award

Speaker: Dr. Lindsay Fourman

Moderator: Dr. Breay Paty

Room: 206

At the end of this session, participants should be able to:

• Describe recent advances in genetics and the pathophysiology of lipodystrophy syndromes.
• Describe the clinical features of lipodystrophy, and how it relates to insulin resistant syndromes.
• Describe current and emerging approaches to the management of lipodystrophic and insulin resistance syndromes.